New York, NY (November 9, 2017) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of brentuximab vedotin (ADCETRIS®) to treat patients with certain types of cutaneous T-cell lymphoma (CTCL) who have received at least one…
New York, NY (October 31, 2017) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of acalabrutinib (CALQUENCE) to treat patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. The Bruton…
New York, NY (September 14, 2017) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of copanlisib to treat patients with relapsed indolent follicular lymphoma (FL). The PI3K dual-isoform inhibitor, developed by Bayer, has been…
New York, NY (August 3, 2017) – New York, NY – The U.S. Food and Drug Administration (FDA) announced it has approved the use of ibrutinib (Imbruvica ®) to treat patients with chronic graft versus host disease (cGVHD) who have…
New York, NY (June 5, 2017) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of subcutaneous rituximab (Rituxan ®) to treat patients with previously untreated follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL),…
New York, NY (March 14, 2017) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of pembrolizumab (KEYTRUDA ®) to treat patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three…
Lymphoma Research Foundation publishes White Paper to outline key issues discussed during Oral Therapies workshop In September 2015, The Lymphoma Research Foundation (LRF) convened scientists, clinicians, advocates, pharmaceutical industry representatives, and federal lawmakers and regulators for a workshop on Oral…